The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
Both products are broad-spectrum, foliar insecticides used across wide range of crops
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)